Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs

CURIS INC

2023-FY EPS reported -$8.96 revenue$10,023,000

Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.
Revenue from Erivedge royalties was $2.7M for Q4 2023, flat YoY.
Cash & investments totaled $56.3M at Dec 31, 2023; company expects runway into 2025.
At ASH, emavusertib + ibrutinib achieved CR in 3 of 5 evaluable R/R PCNSL patients after BTKi failure.
Updated TakeAim Leukemia data expected H1 2024; lymphoma combo and triplet combo data in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CURIS INC reported financial results for full year and quarter ended December 31, 2023.

Period: full year and quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 8, 2024, Curis, Inc. announced its financial results for the full year and quarter ended December 31, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-24-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.